|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400092592 |
|
最近更新日期: Date of Last Refreshed on: |
2024-11-19 16:57:24 |
|
注册时间: Date of Registration: |
2024-11-19 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
神经调控技术在残疾及老龄人群二便功能障碍防治及康复中的研发与临床示范 |
|
Public title: |
Application of neural regulation technology in prevention, treatment and rehabilitation of defecation dysfunction in disabled and elderly population |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
神经调控技术在残疾及老龄人群二便功能障碍防治及康复中的研发与临床示范 |
|
Scientific title: |
Application of neural regulation technology in prevention, treatment and rehabilitation of defecation dysfunction in disabled and elderly population |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈国庆 |
研究负责人: |
廖利民 |
|
Applicant: |
Guoqing Chen |
Study leader: |
Limin Liao |
|
申请注册联系人电话: Applicant telephone: |
+86 18618266386 |
研究负责人电话: Study leader's telephone: |
+86 10 87569043 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
cgq_2000@126.con |
研究负责人电子邮件: Study leader's E-mail: |
lmliao@263.net |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市丰台区角门北路10号 |
研究负责人通讯地址: |
北京市丰台区角门北路10号 |
|
Applicant address: |
No. 10, North Jiao Men Road, Fengtai District, China |
Study leader's address: |
No. 10, Jiaomen North Road, Fengtai District |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
北京博爱医院 |
||
|
Applicant's institution: |
Beijing Boai Hospital |
||
|
研究负责人所在单位: |
北京博爱医院 |
||
|
Affiliation of the Leader: |
Beijing Bo'ai Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2021-095-1 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国康复研究中心医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of China Rehabilitation Research Center |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-09-06 00:00:00 |
||
|
伦理委员会联系人: |
孟丽君 |
||
|
Contact Name of the ethic committee: |
Lijun Meng |
||
|
伦理委员会联系地址: |
北京市丰台区角门北路10号 |
||
|
Contact Address of the ethic committee: |
No. 10, Jiaomen North Road, Fengtai District |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 87020512 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
menglydia@126.com |
|
研究实施负责(组长)单位: |
北京博爱医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Beijing Bo'ai Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市丰台区角门北路10号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 10, Jiaomen North Road, Fengtai District |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
首都卫生发展科研专项项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Capitals Funds for Health Improvement and Research |
||||||||||||||||||||||
|
Target disease: |
Fecal dysfunction |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
我们旨在研发用于治疗老残人群二便功能障碍的便携式,可家用的神经调控产品,包括:无线蓝牙手机APP程控胫神经刺激器和微型便携式智能膀胱腔内电刺激器,并进行多中心临床示范 |
||||||||||||||||||||||
|
Objectives of Study: |
We aim to develop portable, home-ready neuroregulatory products for the treatment of fecal dysfunction in the elderly and disabled, including: Wireless Bluetooth mobile phone APP-controlled tibial nerve stimulator and micro-portable intelligent bladder cavity electrical stimulator, and multi-center clinical demonstration |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1)无线蓝牙手机 APP 程控胫神经刺激器试验: (1)年龄 60-75 周岁(含边界值),性别不限; (2)符合《2019 版中国泌尿外科和男科疾病诊断治疗指南》膀胱过度活动 症诊断标准; (3)同意接受穿戴式经皮胫神经刺激系统(TTNS)治疗; (4)自愿参加本次临床试验,并签署知情同意书; (5)服用β3 受体激动剂或抗胆碱能药物疗效不满意或者因服用抗胆碱能 药物产生的不良反应不耐受的,或不愿意口服药物的患者; (6)排尿日记(随机入组前 3 天)显示平均每 24 小时排尿次数≥8 次的患 者; (7)如拟在研究期间不合并服用β3 受体激动剂或抗胆碱能药物者,需在 筛选期前停用抗胆碱能药物≥7 天。如拟在研究期间继续服用β3 受体激动剂或 抗胆碱能药物者,需保持用量用法不变,直至完成试验。 (8)能够与研究者良好交流并愿意遵照整个试验要求。 2)微型便携式智能膀胱腔内电刺激器试验: (1)年龄 60-75 周岁(含边界值),性别不限; (2)已经确诊为 UAB,且病程大于 3 个月以上的患者; (3)既往常规进行间歇导尿排空膀胱,或具有间歇性导尿指证(残余尿量占 功能膀胱容量 40%以上)的患者; (4)自愿签署书面知情同意书者; (5)能够与研究者良好交流并愿意遵照整个试验要求者。 |
||||||||||||||||||||||
|
Inclusion criteria |
1) Wireless Bluetooth mobile phone APP program-controlled tibial nerve stimulator test: (1) Age 60-75 years old (including boundary value), gender is not limited; (2) Excessive bladder activity in accordance with the "2019 Chinese Guidelines for the Diagnosis and Treatment of Urological and Andrological Diseases". diagnostic criteria; (3) agree to receive wearable percutaneous tibial nerve stimulation system (TTNS) therapy; (4) Voluntarily participate in this clinical trial and sign the informed consent form; (5) Unsatisfactory efficacy of taking β3 agonists or anticholinergic drugs, or due to taking anticholinergics Patients who are intolerant of adverse reactions produced by drugs, or who are unwilling to take oral drugs; (6) The voiding diary (3 days before randomization) showed an average of 8 urination times per 24 hours ≥ He who; (7) If you intend to take β3 agonists or anticholinergic drugs during the study period, you need to be in Discontinuation of anticholinergic drugs for ≥ 7 days prior to the screening period. If you intend to continue taking beta3 agonists for the duration of the study or For anticholinergic drugs, the dosage should be kept unchanged until the test is completed. (8) Able to communicate well with the investigator and be willing to comply with the requirements of the whole trial. 2) Micro portable intelligent intravesical electrical stimulator test: (1) Age 60-75 years old (including boundary value), gender is not limited; (2) Patients who have been diagnosed with UAB and whose disease duration is more than 3 months; (3) Previous routine intermittent catheterization to empty the bladder, or with intermittent catheterization indications (residual urine volume functional bladder capacity of more than 40%); (4) Those who voluntarily signed a written informed consent form; (5) Able to communicate well with the investigator and willing to comply with the requirements of the whole trial. |
||||||||||||||||||||||
|
排除标准: |
1)无线蓝牙手机 APP 程控胫神经刺激器试验: (1)安装起搏器者(电刺激对起搏器安全性影响); (2)合并有未控制的症状性泌尿系感染、膀胱肿瘤、泌尿系结石者; (3)肾积水合并对应侧出现腰胀或腰痛临床症状,且血肌酐>1.2 倍正常 值上限的患者; (4)癫痫患者,老年性痴呆、脑萎缩、脑血管疾病急性期、认知能力障碍 者、帕金森、脊髓完全损伤的患者; (5)精神疾患不能与医生合作者; (6)治疗部位皮肤病损,不能行刺激者; (7)存在恶性肿瘤等严重影响健康的伴随性疾病; (8)III 级及 III 级以上盆腔器官脱垂患者; (9)存在影响试验疗效的其他伴随疾病; (10)残余尿量大于 100 毫升的患者; (11)需要留置尿管或间歇导尿排空膀胱的患者; (12)孕妇、哺乳期妇女、研究期间计划受孕或无安全性避孕措施的育龄妇 女; (13)入组前 1 个月内参加了其他药物或器械临床试验; (14)其他研究者认为不适合入选的情况 2)微型便携式智能膀胱腔内电刺激器试验: (1)尿动力学检查中,膀胱顺应性过低(小于 20ml/cmH2O)的患者; (2)合并流出道机械性梗阻的患者; (3)完全性脊髓损伤患者; (4)合并症状性泌尿系感染者; (5)合并肾积水或膀胱-输尿管返流的患者; (6)合并肾功能不全(血肌酐大于正常值上限的 1.5 倍)的患者; (7)膀胱及前列腺恶性肿瘤患者; (8)体内已植入起搏器或去纤颤器患者; (9)老年性痴呆、脑萎缩、脑血管疾病急性期、认知能力障碍者; (10)癫痫、精神疾患不能与医生合作者; (11)术前感染性疾病筛查(乙肝表面抗原、丙肝抗体、梅毒抗体和 HIV 抗 体) 阳性的患者; (12)孕妇或准备怀孕的患者; (13)试验前 3 个月参加过其它临床试验者; (14)研究者认为不宜参加研究的其他情况。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1) Wireless Bluetooth mobile phone APP program-controlled tibial nerve stimulator test: (1) Those who install a pacemaker (the impact of electrical stimulation on the safety of the pacemaker); (2) Patients with uncontrolled symptomatic urinary tract infection, bladder tumor, and urinary calculus; (3) Hydronephrosis combined with clinical symptoms of lumbar distension or low back pain on the opposite side, and the serum creatinine > 1.2 times normal Patients with upper limit of values; (4) Epilepsy patients, senile dementia, cerebral atrophy, acute phase of cerebrovascular disease, cognitive impairment , Parkinson's, patients with complete spinal cord injury; (5) Those with mental disorders who cannot cooperate with doctors; (6) Skin lesions at the treatment site that cannot be stimulated; (7) The presence of malignant tumors and other concomitant diseases that seriously affect health; (8) Able to communicate well with the investigator and be willing to comply with the requirements of the whole trial. 2) Micro portable intelligent intravesical electrical stimulator test: (1) Age 60-75 years old (including boundary value), gender is not limited; (2) Patients who have been diagnosed with UAB and whose disease duration is more than 3 months; (3) Previous routine intermittent catheterization to empty the bladder, or with intermittent catheterization indications (residual urine volume functional bladder capacity of more than 40%); (4) Those who voluntarily signed a written informed consent form; (5) Able to communicate well with the investigator and willing to comply with the requirements of the whole trial. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-01-01 00:00:00至 To 2024-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2022-07-04 00:00:00 至 To 2024-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由研究者用计算机软件自动生成随机数 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Computer software automatically generates random numbers |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
单盲,对研究参与者设盲 |
|
Blinding: |
Single-blind, blinding of study participants |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究结束后,通过ResMan(www.medresman.org.cn)方式共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After the end of the study, it was shared by ResMan (www.medresman.org.cn). |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |